DataVXACS NanoPaper
journal article·2017-09-26

Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy

Tianjiao Ji, Jiayan Lang, Jing Wang, Rong Cai, Yinlong Zhang, Feifei Qi, Lijing Zhang, Xiao Zhao, Wenjing Wu, Jihui Hao, Zhihai Qin, Ying Zhao, Guangjun Nie

ACS Nano· Volume 11· Issue 9
Publisher page
Source abstract

Abstract

During pancreatic tumor development, pancreatic stellate cells (PSCs) proliferate exuberantly to secrete extracellular matrix (ECM) in the tumor stroma, which presents major barriers for drug delivery and penetration in tumor tissue. Thus, down-regulating ECM levels via regulation of the PSCs may allow enhanced penetration of therapeutic drugs and thereby enhancing their therapeutic efficacy. To regulate the PSCs, a matrix metalloproteinase-2 (MMP-2) responsive peptide-hybrid liposome (MRPL) was constructed via coassembly of a tailor-designed MMP-2 responsive amphiphilic peptide and phospholipids. By utilizing the MMP-2-rich pathological environment, the pirfenidone (PFD) loaded MRPL (MRPL-PFD) can specifically release PFD at the pancreatic tumor site and down-regulate the multiple components of ECM expressed by the PSCs. This resulted in a significant increase in the penetration of gemcitabine into the tumor tissue and enhanced the efficacy of gemcitabine for pancreatic tumor. Our design tailored for antifibrosis of pancreatic cancer may provide a practical approach to build functional liposomes through supramolecular assembly, and regulation of ECM may be a promising adjuvant therapeutic strategy for pancreatic and other ECM-rich tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Peptidase Inhibition and Analysis · Pancreatic and Hepatic Oncology Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China

University of Chinese Academy of Sciences, Beijing 100049, China

Sino-Danish Center for Education and Research, Sino-Danish College of UCAS, Beijing 100190, China

College of Pharmaceutical Science, Jilin University, Changchun 130021, China

Department of Pancreatic Carcinoma Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Funding

Ministry of Science and Technology of the People's Republic of China · Natural Science Foundation of Beijing Municipality · Youth Innovation Promotion Association of the Chinese Academy of Sciences · National Natural Science Foundation of China · Beijing Nova Program · Chinese Academy of Sciences · Beijing Municipal Science and Technology Commission

References (52)

Show source-provided references
1. 10.1136/gut.2010.22609210.1136/gut.2010.226092 ↗
2. 10.1136/gutjnl-2015-30930410.1136/gutjnl-2015-309304 ↗
3. 10.1158/1078-0432.CCR-11-311410.1158/1078-0432.CCR-11-3114 ↗
4. 10.1038/nrclinonc.2009.23610.1038/nrclinonc.2009.236 ↗
5. 10.3322/caac.2133210.3322/caac.21332 ↗
6. 10.1093/annonc/mdv00110.1093/annonc/mdv001 ↗
7. 10.1002/adma.20140471510.1002/adma.201404715 ↗
8. 10.1021/acsami.5b1161910.1021/acsami.5b11619 ↗
9. 10.1021/nn402644g10.1021/nn402644g ↗
10. 10.1053/j.gastro.2012.11.03710.1053/j.gastro.2012.11.037 ↗
11. 10.1172/JCI3008210.1172/JCI30082 ↗
12. 10.1016/j.cgh.2009.07.03810.1016/j.cgh.2009.07.038 ↗
13. 10.1242/jcs.02382010.1242/jcs.023820 ↗
14. 10.1053/j.gastro.2004.12.03610.1053/j.gastro.2004.12.036 ↗
15. 10.1038/ncb165810.1038/ncb1658 ↗
16. 10.1038/nrgastro.2012.11510.1038/nrgastro.2012.115 ↗
17. 10.1158/1078-0432.CCR-03-082510.1158/1078-0432.CCR-03-0825 ↗
18. 10.1371/journal.pone.002168410.1371/journal.pone.0021684 ↗
19. 10.1002/path.193510.1002/path.1935 ↗
20. Sakko A. J. · Cancer Res. · 2001 · 61 · 926
21. 10.1016/j.bbrc.2004.08.00810.1016/j.bbrc.2004.08.008 ↗
22. 10.1007/s11515-014-1300-810.1007/s11515-014-1300-8 ↗
23. 10.1006/jsre.2002.640310.1006/jsre.2002.6403 ↗
24. 10.1242/jcs.0334710.1242/jcs.03347 ↗
25. 10.1016/S0936-6555(05)80269-910.1016/S0936-6555(05)80269-9 ↗
26. 10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
27. 10.1016/S0140-6736(15)00986-110.1016/S0140-6736(15)00986-1 ↗
28. 10.1016/j.tibtech.2013.09.00710.1016/j.tibtech.2013.09.007 ↗
29. 10.1016/j.jconrel.2014.10.00510.1016/j.jconrel.2014.10.005 ↗
30. 10.1080/14737140.2016.117458110.1080/14737140.2016.1174581 ↗
31. 10.1021/nn300524f10.1021/nn300524f ↗
32. 10.1021/nn403395410.1021/nn4033954 ↗
33. 10.3109/10717544.2015.100870710.3109/10717544.2015.1008707 ↗
34. 10.1016/j.jconrel.2015.05.21610.1016/j.jconrel.2015.05.216 ↗
35. 10.1021/nn302148p10.1021/nn302148p ↗
36. 10.1021/nn501162x10.1021/nn501162x ↗
37. 10.1021/nn304474j10.1021/nn304474j ↗
38. 10.1016/j.jconrel.2016.09.03210.1016/j.jconrel.2016.09.032 ↗
39. 10.1002/smll.20130016110.1002/smll.201300161 ↗
40. 10.1016/j.jconrel.2011.06.03210.1016/j.jconrel.2011.06.032 ↗
41. 10.1038/nrd349510.1038/nrd3495 ↗
42. 10.1016/j.jconrel.2005.12.02310.1016/j.jconrel.2005.12.023 ↗
43. 10.1159/00032071110.1159/000320711 ↗
44. 10.1053/j.gastro.2016.03.04010.1053/j.gastro.2016.03.040 ↗
45. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
46. 10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗
47. 10.1038/onc.2013.2310.1038/onc.2013.23 ↗
48. 10.1101/gad.175380910.1101/gad.1753809 ↗
49. 10.1097/00006676-200104000-0001110.1097/00006676-200104000-00011 ↗
50. Mackey J. R. · Cancer Res. · 1998 · 58 · 4349
51. 10.1136/gut.43.1.12810.1136/gut.43.1.128 ↗
52. 10.1016/S0016-5085(98)70209-410.1016/S0016-5085(98)70209-4 ↗